Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 17 of 17 matching drugs for HTR4 — including drugs targeting any of its 13 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
dexamethasone, ondansetron, quality-of-life assessment HTR4 Direct 1
amisulpride HTR4 Direct yes 0
cisapride HTR4 Direct yes 0
clebopride HTR4 Direct yes 0
dexfenfluramine HTR4 Direct yes 0
dexfenfluramine hydrochloride HTR4 Direct yes 0
metoclopramide HTR4 Direct yes 0
metoclopramide hydrochloride HTR4 Direct yes 0
prucalopride HTR4 Direct yes 0
prucalopride succinate HTR4 Direct yes 0
tegaserod maleate HTR4 Direct yes 0
unnamed compound HTR4 Direct yes 0
zimeldine HTR4 Direct yes 0
zimeldine hydrochloride HTR4 Direct yes 0
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy NFKB2 SSL via NFKB2 1
sulfasalazine NFKB2 SSL via NFKB2 1
ataluren RPL22 SSL via RPL22 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.